These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25427433)

  • 1. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.
    Ruangwattanapaisarn N; Hsiao A; Vasanawala SS
    Pediatr Radiol; 2015 Jun; 45(6):831-9. PubMed ID: 25427433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol.
    Luhar A; Khan S; Finn JP; Ghahremani S; Griggs R; Zaritsky J; Salusky I; Hall TR
    Pediatr Radiol; 2016 Aug; 46(9):1332-40. PubMed ID: 27059620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
    Ning P; Zucker EJ; Wong P; Vasanawala SS
    Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia.
    Lai LM; Cheng JY; Alley MT; Zhang T; Lustig M; Vasanawala SS
    J Magn Reson Imaging; 2017 May; 45(5):1407-1418. PubMed ID: 27678106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol.
    Shahrouki P; Khan SN; Yoshida T; Iskander PJ; Ghahremani S; Finn JP
    Pediatr Radiol; 2022 Mar; 52(3):501-512. PubMed ID: 34936018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.
    Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
    Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.
    Nguyen KL; Park EA; Yoshida T; Hu P; Finn JP
    J Cardiovasc Magn Reson; 2017 Dec; 19(1):106. PubMed ID: 29284494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
    Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
    Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.
    Dasi A; Kring DN; Selvaraj B; Morgan P; Gerity C; Morgan EE; Krishnamurthy R; Krishnamurthy R
    Pediatr Radiol; 2023 Dec; 53(13):2622-2632. PubMed ID: 37837456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.
    Stabi KL; Bendz LM
    Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation.
    Smits LP; Tiessens F; Zheng KH; Stroes ES; Nederveen AJ; Coolen BF
    Atherosclerosis; 2017 Aug; 263():211-218. PubMed ID: 28662398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.
    Shahrouki P; Moriarty JM; Khan SN; Bista B; Kee ST; DeRubertis BG; Yoshida T; Nguyen KL; Finn JP
    J Cardiovasc Magn Reson; 2019 Mar; 21(1):17. PubMed ID: 30853026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent.
    Li W; Tutton S; Vu AT; Pierchala L; Li BS; Lewis JM; Prasad PV; Edelman RR
    J Magn Reson Imaging; 2005 Jan; 21(1):46-52. PubMed ID: 15611942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
    Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
    Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary MRA During Pregnancy: Early Experience With Ferumoxytol.
    Starekova J; Nagle SK; Schiebler ML; Reeder SB; Meduri VN
    J Magn Reson Imaging; 2023 Jun; 57(6):1815-1818. PubMed ID: 36315131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution 3D volumetric contrast-enhanced MR angiography with a blood pool agent (ferumoxytol) for diagnostic evaluation of pediatric brain arteriovenous malformations.
    Iv M; Choudhri O; Dodd RL; Vasanawala SS; Alley MT; Moseley M; Holdsworth SJ; Grant G; Cheshier S; Yeom KW
    J Neurosurg Pediatr; 2018 Sep; 22(3):251-260. PubMed ID: 29882734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blood pool and extracellular contrast agents for pediatric and young adult cardiovascular magnetic resonance imaging.
    Johnson JT; Robinson JD; Deng J; Rigsby CK
    Pediatr Radiol; 2016 Dec; 46(13):1822-1830. PubMed ID: 27576457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
    Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
    Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease.
    Walker JP; Nosova E; Sigovan M; Rapp J; Grenon MS; Owens CD; Gasper WJ; Saloner DA
    Ann Vasc Surg; 2015 Jan; 29(1):63-8. PubMed ID: 25269682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of ferumoxytol for high-resolution vascular imaging and troubleshooting for abdominal allografts.
    Shah A; Neitzel E; Panda A; Fananapazir G
    Abdom Radiol (NY); 2024 Aug; 49(8):2858-2872. PubMed ID: 38561553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.